Vasomotor Symptoms (VMS) are one of the major symptoms of menopause that principally includes hot flashes (HF) and night sweats (NS) during menopause and occurs in majority of women across the globe. A woman with VMS, experiences abundant heat accompanied by sweating and flushing, especially around head, neck, chest, and upper back region. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones.
Scope of Vasomotor Symptoms Report
Night sweats are Hot Flashes that occur with heavy perspiration during sleep and cause sleep disruption. Women experiencing night sweats have greater motor restlessness in bed, less efficient sleep and a reduced feeling of restlessness in the morning compared to women without these symptoms.
Drugs covered1. Donesta2. NT-8143. FP-1014. Fezolinetant5. SJX 6536. MT-8554And many others
The key players in Vasomotor Symptoms market are:1. Mithra Pharmaceuticals (Donesta Biosciences)2. KaNDy Therapeutics3. Fervent Pharmaceuticals4. Astellas Pharma5. Sojournix6. Mitsubishi Tanabe PharmaAnd many others
Request for sample pagesTable of contents
1. Report Introduction
2. Vasomotor Symptoms of Menopause
2.1. Overview
2.2. History
2.3. Vasomotor Symptoms of Menopause Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Vasomotor Symptoms of Menopause Diagnosis
2.6.1. Diagnostic Guidelines
3. Vasomotor Symptoms of Menopause Current Treatment Patterns
3.1. Vasomotor Symptoms of Menopause Treatment Guidelines
4. Vasomotor Symptoms of Menopause – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Vasomotor Symptoms of Menopause companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Vasomotor Symptoms of Menopause Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Vasomotor Symptoms of Menopause Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Vasomotor Symptoms of Menopause Late Stage Products (Phase-III)
7. Vasomotor Symptoms of Menopause Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Vasomotor Symptoms of Menopause Discontinued Products
13. Vasomotor Symptoms of Menopause Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report
14. Vasomotor Symptoms of Menopause Key Companies
15. Vasomotor Symptoms of Menopause Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Vasomotor Symptoms of Menopause Unmet Needs
18. Vasomotor Symptoms of Menopause Future Perspectives
19. Vasomotor Symptoms of Menopause Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/